By the Numbers

Pfizer Earnings By the Numbers

Pfizer, the world's largest drugmaker, is scheduled to repo

Pfizer headquarters in New York City.
Getty Images

rt fourth-quarter results before the opening bell on Wednesday, February 3. 

The consensus First Call EPS estimate stands at $0.50 compared to last year's gain of $0.65, while revenue is expected to increase by 29.7% to $15.97 billion. 

What follows are some facts and figures on how Pfizer  shares traded in the most recent earnings reports. 


  • Beat revenue estimates for 4 of the past 8 quarters

  • Beat EPS estimates for 7 of the past 8 quarters

  • Beat annual EPS estimates for 3 of the past 5 years

  • Dollar impact? In 2008, 58% of revenue was derived from outside the United States

  • Pfizer shares are up 3% in 2010, and 49% since the March low

  • Competitors' Performance in 2010: Merck +5%, Novartis -0.7%, Amgen +4% and Biogen Idec +0.8%

  • Pfizer shares hit a new 52-week high of $20.36 on January 20, 2010

  • The company's shares are trading 0.8% above their 50-day moving average

Stock Performance By The Numbers

  • In the past 8 quarters, Pfizer  shares rose 1.57%, on average, the day before the company reported its quarterly results
  • Pfizer shares have a bearish trend that peaks 4 days after earnings.  It has declined 8 times after the past 10 earnings reports, posting an overall average loss of 2% (

S&P Healthcare Sector:

  • Best performing sector so far in 2010, up 0.9%
  • Leaders year-to-date: Humana +11%, Genzyme +10.6% and Gilead Sciences +10.5%
  • Losers year-to-date: Forest Laboratories -8%, Allergan -8% and Waters Corp. -7.7%

Earning Estimates Source: CNBC & Thomson Reuters